Skip to Main Content

Paper Details

Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic.
Br J Ophthalmol
13
2021
COVID-19, IMT, NIU, coronavirus disease-2019, corticosteroids, hydroxychloroquine, non-infectious uveitis, patients, scleritis, uveitis
COVID-19, Clinical Decision-Making, Consensus, Cross-Sectional Studies, Glucocorticoids, Humans, Immunomodulation, Immunosuppressive Agents, Practice Guidelines as Topic, Risk Assessment, SARS-CoV-2, Surveys and Questionnaires, Uveitis
Author NameAffiliation
Rupesh AgrawalNational Healthcare Group Eye Institute, Tan Tock Seng Hospital
Rupesh AgrawalSingapore Eye Research Institute
Rupesh AgrawalNanyang Technological University
Rupesh AgrawalMoorfields Eye Hospital, NHS Foundation Trust
Ilaria TestiMoorfields Eye Hospital, NHS Foundation Trust
Cecilia S LeeUniversity of Washington
Edmund Tsuiuniversity of california los angeles Stein Eye Institute and Department of Ophthalmology, David Geffen School of Medicine at university of california los angeles, University of California
Marian BlazesUniversity of Washington
Jennifer E ThorneWilmer Eye Institute, Johns Hopkins University School of Medicine
Annabelle A OkadaKyorin University School of Medicine
Justine R SmithFlinders University College of Medicine and Public Health
Peter McCluskeyDirector Save Sight Institute, The University of Sydney
John H KempenMassachusetts Eye and Ear Infirmary and Harvard Medical School
John H KempenMyungSung Christian Medical Center, MCM General Hospital and MyungSung Medical School
Christoph TappeinerBern University Hospital, University of Bern
Manisha Agarwal
Bahram BodaghiSorbonne University
Quan Dong NguyenByers Eye Institute, Stanford Medical School
Vishali GuptaPostgraduate Institute of Medical Education (PGIMER)
Marc D de Smet
Manfred ZierhutUniversity of Tuebingen
Carlos PavesioMoorfields Eye Hospital, NHS Foundation Trust
  • 1 - 22

Datasets